Session 3: Monitoring and Managing Infections in Patients with MM Treated with Bispecific Antibodies : Episode 6
Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
Experts discuss how they educate infusion nurses and other colleagues treating patients with multiple myeloma on the infection risks of BCMA-targeting bispecific antibodies.
EP: 1.Overview of Bispecific Antibodies in Multiple Myeloma Treatment
EP: 2.Infection Patterns of Bispecific Antibodies in Multiple Myeloma Treatment
EP: 3.Patient Case 1: A 69-Year-Old Male With Relapse/Refractory IgG Lambda Multiple Myeloma
EP: 4.Patient Case 2: A 74-Year-Old Male With Kappa LC Multiple Myeloma
EP: 5.Patient Case 3: A 79-Year-Old Female With IgG Kappa Multiple Myeloma
Now Viewing
EP: 6.Educating Infusion Nurses on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
EP: 7.Data on Infections and Severe Hypogammaglobulinemia in MM Patients Treated with Anti-BCMA Bispecific Antibodies
EP: 8.Bacterial Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
EP: 9.Viral Infections in Patients With MM Treated with Anti-BCMA Bispecific Antibodies
EP: 10.Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM Treatment
EP: 11.Recap: Mitigation of CRS and ICANS During Bispecific Treatment in Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
